MAXCYTE, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MXCT in the last 30 days.
See all $MXCT insider activity →MaxCyte Inc (MXCT) shares rose 25% after raising its 2026 revenue guidance to $34M from $30M-$32M, citing strong Q3 results. Q3 core revenue was $8.1M, up 26% YoY, exceeding estimates. The company also reported $1M in SPL-related revenue. Updated guidance reflects 15% YoY growth in core revenue for H2 2026.
MAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, MD, October 14, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-en
MaxCyte (MXCT) reported Q2 2026 revenues ahead of expectations, with sequential growth driven by instrument placements, including its DTx platform. The company reduced net loss YoY and announced a multiplatform technology license partnership with Genentech, reflecting growing recognition of MaxCyte's technology. The partnership supports multiple programs and diversifies MaxCyte's revenue streams. Vertex's CASGEVY revenue grew 75% sequentially and 150% YoY, contributing to MaxCyte's SPL program-r
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning MXCT (MAXCYTE, INC.). Coverage has skewed bullish: 8 bullish, 0 neutral, and 0 bearish.
Recent MXCT coverage spans earnings, technology and mergers & acquisitions.
Guidance beat and strong Q3 results likely support further upside.
Raised guidance suggests stronger top‑line growth and may lift the stock.
Positive outlook from management may support short-term price stability.
The new assays expand MaxCyte's SeQure service, potentially increasing demand from gene‑editing developers.
New service expands MaxCyte's SeQure portfolio, potentially increasing demand from gene‑editing developers.
AlphAI scores every news story that mentions MXCT with an AI model for sentiment and relevance, and aggregates insider trades from MAXCYTE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
MaxCyte Inc (MXCT) shares rose 25% after raising its 2026 revenue guidance to $34M from $30M-$32M, citing strong Q3 results. Q3 core revenue was $8.1M, up 26% YoY, exceeding estimates. The company also reported $1M in SPL-related revenue. Updated guidance reflects 15% YoY growth in core revenue for H2 2026.
1 min readMAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 ROCKVILLE, MD, October 14, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-en
2 min readMaxCyte (MXCT) reported Q2 2026 revenues ahead of expectations, with sequential growth driven by instrument placements, including its DTx platform. The company reduced net loss YoY and announced a multiplatform technology license partnership with Genentech, reflecting growing recognition of MaxCyte's technology. The partnership supports multiple programs and diversifies MaxCyte's revenue streams. Vertex's CASGEVY revenue grew 75% sequentially and 150% YoY, contributing to MaxCyte's SPL program-r
2 min readMaxCyte (MXCT) launched CHANGE-seq-BE and ONE-seq-BE assays to help therapeutic developers assess off-target risks in base editing therapies. The assays aim to identify potential off-target editing sites and genetic variants, supporting regulatory compliance and clinical development. MXCT's stock closed at $1.27, down 3.79%, and is down 0.47% in premarket trading.
2 min readMaxCyte, Inc. (NASDAQ: MXCT) launched CHANGE-seq-BE and ONE-seq-BE assays for off-target assessment in genome editing therapies. These assays, part of MaxCyte's SeQure service, aim to enhance safety evaluation for base editors, aligning with FDA guidelines. The company positions itself as a single-source provider for orthogonal nomination assays, supporting therapeutic developers in clinical development.
1 min readMaxCyte reported Q2 2026 sequential revenue growth after inventory drawdowns from a major customer and clinical program discontinuations. It signed a multi-platform enterprise partnership with Genentech and expects 2026 revenue guidance of $30m to $32m. Operating expenses fell 25% YoY. Company plans to use most of a $10m share repurchase program and expects mid-70s gross margins.
6 min readMaxCyte Inc (NASDAQ: MXCT) reported Q2 2026 EPS of $(0.08), better than the $(0.09) consensus, and revenue of $7.271M versus $6.475M consensus. Sales fell 14.53% year over year. The company signed a multi-platform technology license partnership with Genentech and reiterated 2026 guidance for $30M to $32M revenue.
5 min readMAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MaxCyte Reports Second Quarter 2026 Financial Results · Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue · Reiterates Full Year 2026 Guidance · Repurchased a
6 min readMaxCyte (MXCT) said it signed a multi-platform technology license partnership with Genentech, a Roche Group member (RHHBY), to support next-generation cell therapy programs. Genentech will access MaxCyte’s ExPERT GTx platform and other technologies across research, clinical development, and manufacturing workflows. MaxCyte’s stock closed at $1.23, up 5.13% on the day.
3 min readMAXCYTE, INC. (MXCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. MaxCyte, Inc._June 17, 2026 0001287098 false 0001287098 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of e
2 min read
